Your doctor may tell you that your chemotherapy treatment will most likely lead to
hair loss. In addition to scalp hair loss, you may also lose your eyebrows. While scalp
hair loss can be disguised, the loss of eyebrows can be di;cult to conceal and is often
perceived by patients as an unwelcome, visible sign of their illness.
RMV Trademarks, LLC, has developed a unique, patented product called EES-Essential
Eyebrow Solution®. EES is a clinically-tested, topical formulation that is used
cosmetically to address eyebrow thinning or loss, while conditioning and revitalizing
the brows. EES is safe and non-irritating, paraben-free, hypoallergenic, and pH
A recent EES clinical trial published in PRIME International Journal of Aesthetic &
Anti-Ageing Medicine demonstrated that 91% of the 117 enrolled cancer patients
retained 50-100% of their eyebrow hair while undergoing chemotherapy
treatment, despite experiencing full body hair loss elsewhere. The article
“Preserving Eyebrow Hair during Chemotherapy Treatment” was written in
collaboration with Josephine Ford Cancer Institute/Henry Ford Health System,
located in Detroit, Michigan.
10% of proceeds donated to Look Good Feel Better®
during Breast Cancer Awareness Month
Introducing EES – Essential Eyebrow Solution®
. . . A Solution for a Problem
TO LEARN MORE ABOUT EES, please visit www.essentialeyebrowsolution.com, or call 1-888-208-5081.
Chemotherapy regimen consisted of: Perjeta, Taxotere,
Carboplatin & Herceptin (every 3 weeks x 6 cycles),
followed by Herceptin every 3 weeks for 1 year.
The ability to maintain my natural eyebrows
during my treatment made a signi;cant
psychological di;erence when dealing with
my other losses. With a wig, eyeliner and the
preservation of my own eyebrows, others
frequently commented on their amazement
that I had not lost my hair... when indeed I
had. The loss of eyelashes and the hair on
one’s head are far easier to conceal than the
loss of one’s eyebrows. Thank you for the
opportunity to use this product during my
” — Lynn
Patient retained her eyebrows despite
full body hair loss elsewhere
which have already been shown to delay relapse by
over a year. Rosenblatt thinks that for blood cancers,
as for solid tumors, future treatment regimens will
likely include combinations of immunotherapies.
“But first we have to understand which combinations have the best synergy,” she says.
Over the years since being treated with the vaccine,
Liebert has had relapses and received a number of
therapies. In 2013, he was treated with radiation for a
concentration of myeloma cells in a neck vertebra; in
2015, blood tests and a bone marrow biopsy showed
that he had relapsed, and he received Kyprolis
(carfilzomib) and Pomalyst (pomalidomide).
“You know you’re going to relapse pretty much
until you reach an endpoint, which is either A,
your death, or B, they find a cure,” he says. “I never
thought I’d hit 60.”
Given the choice, he says he’d participate in the
vaccine trial again—even without knowing the
results. Rosenblatt notes that some people may be
skeptical of clinical trials and afraid to try some-
thing that’s not proven. “Other people, at the other
end, may have unrealistic hopes about what a trial
can offer,” she says. It’s up to the researchers, she
adds, to present information in a clear way that
conveys the possible outcomes.
It’s also up to the researchers to identify the
patient population most likely to respond. “If it
works, I hope it works in everybody,” says Gilbert.
“If it works in some people and not in others, we
need to figure out why.”
STEPHEN ORNES, a contributing writer for Cancer Today, lives in